Banco Santander SA Stock News

Dupixent® (dupilumab) : premier et seul médicament ciblé approuvé par la Commission européenne pour le traitement de la dermatite atopique sévère de l’enfant à partir de six mois

Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis

A white-shoe law firm is working with Credit Suisse bondholders to pursue "possible legal actions" after the value of convertible bonds issued by the bank was written down to zero following the takeov

Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

Des données de dernière heure sur Dupixent® (dupilumab) présentées au Congrès de l’AAD montrent des améliorations significatives des signes et symptômes de la dermatite atopique des mains et

The Mexican arm of Spain's Banco Santander plans to launch digital lender Openbank by the end of March 2024 to offer checking accounts, credit cards and other services over time, the head of the local

European banking shares were hammered on Wednesday as confidence in the sector already rattled by the collapse of Silicon Valley Bank in the US was knocked further by a fall of more than 25% in the va

Peter Boockvar, Bleakley Financial Group CIO and CNBC contributor, joins 'Squawk Box' to make some understanding of the bank stock performance in Europe, if the plummet in European bank stocks has any

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement

Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marc

Here are some of the biggest movers on Monday with banks in focus after federal regulators stepped into protect deposits at fallen bank SVB.

One casualty of regulators rescuing SVB depositors? There will be no March rate hike, says Goldman Sachs.

Sanofi va acquérir Provention Bio, Inc. – une opération qui enrichit son portefeuille et lui adjoint TZIELD, premier traitement modifiant l’évolution du diabète de type 1 et retardant la phase